Semin Respir Crit Care Med 2011; 32(6): 745-753
DOI: 10.1055/s-0031-1295722
© Thieme Medical Publishers

Pulmonary Blastomycosis

J. Ryan Bariola1 , 2 , Keyur S. Vyas1 , 2
  • 1Division of Infectious Diseases, University of Arkansas for Medical Sciences, Little Rock, Arkansas
  • 2Central Arkansas Veterans Healthcare System, Little Rock, Arkansas
Further Information

Publication History

Publication Date:
13 December 2011 (online)

ABSTRACT

Blastomyces dermatitidis is acquired in almost all cases via inhalation, and pulmonary disease is the most frequent clinical manifestation of blastomycosis. Pulmonary disease can range from asymptomatic infection to rapidly severe and fatal disease. Most cases will present as pneumonia, either acute or chronic, or as a lung mass. In rare cases pulmonary blastomycosis is associated with the acute respiratory distress syndrome. Blastomycosis can present as isolated pulmonary disease or along with coexisting extrapulmonary disease that usually will involve the skin, bony structures, genitourinary tract, or central nervous system. Diagnosis is largely based on isolation of the organism via culture or visualization of the organism in clinical specimens. Detection of urinary Blastomyces antigen is a recent addition to diagnostic options. Itraconazole is the drug of choice for most forms of the disease; amphotericin B is reserved for the more severe forms. Newer azoles such as voriconazole and posaconazole have a limited role in the treatment of pulmonary blastomycosis.

REFERENCES

  • 1 Gilchrist T C, Stokes W R. A case of pseudo-lupus vulgaris caused by a Blastomyces.  J Exp Med. 1898;  3 (1) 53-78
  • 2 Witorsch P, Utz J P. North American blastomycosis: a study of 40 patients.  Medicine (Baltimore). 1968;  47 (3) 169-200
  • 3 Sarosi G A, Davies S F. Blastomycosis.  Am Rev Respir Dis. 1979;  120 (4) 911-938
  • 4 Nemecek J C, Wüthrich M, Klein B S. Global control of dimorphism and virulence in fungi.  Science. 2006;  312 (5773) 583-588
  • 5 Drutz D J, Frey C L. Intracellular and extracellular defenses of human phagocytes against Blastomyces dermatitidis conidia and yeasts.  J Lab Clin Med. 1985;  105 (6) 737-750
  • 6 Sugar A M, Picard M. Macrophage- and oxidant-mediated inhibition of the ability of live Blastomyces dermatitidis conidia to transform to the pathogenic yeast phase: implications for the pathogenesis of dimorphic fungal infections.  J Infect Dis. 1991;  163 (2) 371-375
  • 7 Rocco N M, Carmen J C, Klein B S. Blastomyces dermatitidis yeast cells inhibit nitric oxide production by alveolar macrophage inducible nitric oxide synthase.  Infect Immun. 2011;  79 (6) 2385-2395
  • 8 Hogan L H, Klein B S. Altered expression of surface alpha-1,3-glucan in genetically related strains of Blastomyces dermatitidis that differ in virulence.  Infect Immun. 1994;  62 (8) 3543-3546
  • 9 Newman S L, Chaturvedi S, Klein B S. The WI-1 antigen of Blastomyces dermatitidis yeasts mediates binding to human macrophage CD11b/CD18 (CR3) and CD14.  J Immunol. 1995;  154 (2) 753-761
  • 10 Brandhorst T T, Wüthrich M, Warner T, Klein B. Targeted gene disruption reveals an adhesin indispensable for pathogenicity of Blastomyces dermatitidis.  J Exp Med. 1999;  189 (8) 1207-1216
  • 11 Finkel-Jimenez B, Wüthrich M, Brandhorst T, Klein B S. The WI-1 adhesin blocks phagocyte TNF-alpha production, imparting pathogenicity on Blastomyces dermatitidis.  J Immunol. 2001;  166 (4) 2665-2673
  • 12 Finkel-Jimenez B, Wüthrich M, Klein B S. BAD1, an essential virulence factor of Blastomyces dermatitidis, suppresses host TNF-alpha production through TGF-beta-dependent and -independent mechanisms.  J Immunol. 2002;  168 (11) 5746-5755
  • 13 Zhang M X, Brandhorst T T, Kozel T R, Klein B S. Role of glucan and surface protein BAD1 in complement activation by Blastomyces dermatitidis yeast.  Infect Immun. 2001;  69 (12) 7559-7564
  • 14 Bradsher R W, Chapman S W, Pappas P G. Blastomycosis.  Infect Dis Clin North Am. 2003;  17 (1) 21-40 vii
  • 15 Baumgardner D J, Steber D, Glazier R et al.. Geographic information system analysis of blastomycosis in northern Wisconsin, USA: waterways and soil.  Med Mycol. 2005;  43 (2) 117-125
  • 16 Dworkin M S, Duckro A N, Proia L, Semel J D, Huhn G. The epidemiology of blastomycosis in Illinois and factors associated with death.  Clin Infect Dis. 2005;  41 (12) e107-e111
  • 17 Morris S K, Brophy J, Richardson S E et al.. Blastomycosis in Ontario, 1994-2003.  Emerg Infect Dis. 2006;  12 (2) 274-279
  • 18 Centers for Disease Control and Prevention . Blastomycosis—Wisconsin, 1986–1995.  MMWR Morb Mortal Wkly Rep. 1996;  45 601-603
  • 19 Chu J H, Feudtner C, Heydon K, Walsh T J, Zaoutis T E. Hospitalizations for endemic mycoses: a population-based national study.  Clin Infect Dis. 2006;  42 (6) 822-825
  • 20 Klein B S, Vergeront J M, Weeks R J et al.. Isolation of Blastomyces dermatitidis in soil associated with a large outbreak of blastomycosis in Wisconsin.  N Engl J Med. 1986;  314 (9) 529-534
  • 21 Klein B S, Vergeront J M, DiSalvo A F, Kaufman L, Davis J P. Two outbreaks of blastomycosis along rivers in Wisconsin. Isolation of Blastomyces dermatitidis from riverbank soil and evidence of its transmission along waterways.  Am Rev Respir Dis. 1987;  136 (6) 1333-1338
  • 22 Proctor M E, Klein B S, Jones J M, Davis J P. Cluster of pulmonary blastomycosis in a rural community: evidence for multiple high-risk environmental foci following a sustained period of diminished precipitation.  Mycopathologia. 2002;  153 (3) 113-120
  • 23 Pfister J R, Archer J R, Hersil S et al.. Non-rural point source blastomycosis outbreak near a yard waste collection site.  Clin Med Res. 2011;  9 (2) 57-65
  • 24 Carlos W G, Rose A S, Wheat L J et al.. Blastomycosis in Indiana: digging up more cases.  Chest. 2010;  138 (6) 1377-1382
  • 25 Denton J F, Disalvo A F. Isolation of Blastomyces dermatitidis from natural sites in Augusta, Georgia.  Am J Trop Med Hyg. 1964;  13 716-722
  • 26 Bakerspigel A, Kane J, Schaus D. Isolation of Blastomyces dermatitidis from an earthen floor in southwestern Ontario, Canada.  J Clin Microbiol. 1986;  24 (5) 890-891
  • 27 Burgess J W, Schwan W R, Volk T J. PCR-based detection of DNA from the human pathogen Blastomyces dermatitidis from natural soil samples.  Med Mycol. 2006;  44 (8) 741-748
  • 28 Dwight P J, Naus M, Sarsfield P, Limerick B. An outbreak of human blastomycosis: the epidemiology of blastomycosis in the Kenora catchment region of Ontario, Canada.  Can Commun Dis Rep. 2000;  26 (10) 82-91
  • 29 Vaaler A K, Bradsher R W, Davies S F. Evidence of subclinical blastomycosis in forestry workers in northern Minnesota and northern Wisconsin.  Am J Med. 1990;  89 (4) 470-476
  • 30 Landis F B, Varkey B. Late relapse of pulmonary blastomycosis after adequate treatment with amphotericin B. Case report.  Am Rev Respir Dis. 1976;  113 (1) 77-81
  • 31 Lemos L B, Baliga M, Guo M. Blastomycosis: the great pretender can also be an opportunist: initial clinical diagnosis and underlying diseases in 123 patients.  Ann Diagn Pathol. 2002;  6 (3) 194-203
  • 32 Pappas P G, Pottage J C, Powderly W G et al.. Blastomycosis in patients with the acquired immunodeficiency syndrome.  Ann Intern Med. 1992;  116 (10) 847-853
  • 33 Pappas P G. Blastomycosis in the immunocompromised patient.  Semin Respir Infect. 1997;  12 (3) 243-251
  • 34 Gauthier G M, Safdar N, Klein B S, Andes D R. Blastomycosis in solid organ transplant recipients.  Transpl Infect Dis. 2007;  9 (4) 310-317
  • 35 Harris J R, Blaney D D, Lindsley M D et al.. Blastomycosis in man after kinkajou bite.  Emerg Infect Dis. 2011;  17 (2) 268-270
  • 36 Farber E R, Leahy M S, Meadows T R. Endometrial blastomycosis acquired by sexual contact.  Obstet Gynecol. 1968;  32 (2) 195-199
  • 37 Maxson S, Miller S F, Tryka F, Schutze G E. Perinatal blastomycosis: a review.  Pediatr Infect Dis J. 1992;  11 760-763
  • 38 Bradsher R W, Rice D C, Abernathy R S. Ketoconazole therapy for endemic blastomycosis.  Ann Intern Med. 1985;  103 (6 Pt 1) 872-879
  • 39 Halvorsen R A, Duncan J D, Merten D F, Gallis H A, Putman C E. Pulmonary blastomycosis: radiologic manifestations.  Radiology. 1984;  150 (1) 1-5
  • 40 Sheflin J R, Campbell J A, Thompson G P. Pulmonary blastomycosis: findings on chest radiographs in 63 patients.  AJR Am J Roentgenol. 1990;  154 (6) 1177-1180
  • 41 Brown L R, Swensen S J, Van Scoy R E, Prakash U B, Coles D T, Colby T V. Roentgenologic features of pulmonary blastomycosis.  Mayo Clin Proc. 1991;  66 (1) 29-38
  • 42 Rabinowitz J G, Busch J B, Buttram W R. Pulmonary manifestations of blastomycosis: radiological support of a new concept.  Radiology. 1976;  120 (1) 25-32
  • 43 Bariola J R, Hage C A, Durkin M et al.. Detection of Blastomyces dermatitidis antigen in patients with newly diagnosed blastomycosis.  Diagn Microbiol Infect Dis. 2011;  69 (2) 187-191
  • 44 Hawley C, Felson B. Roentgen aspects of intrathoracic blastomycosis.  Am J Roentgenol Radium Ther Nucl Med. 1956;  75 (4) 751-757
  • 45 O’Marro S D, Varkey B. Unexpected recovery of Blastomyces dermatitidis from an anaerobic pleural empyema.  Am J Med. 1989;  86 (6 Pt 2) 833
  • 46 Arora N S, Oblinger M J, Feldman P S. Chronic pleural blastomycosis with hyperprolactinemia, galactorrhea, and amenorrhea.  Am Rev Respir Dis. 1979;  120 (2) 451-455
  • 47 Griffith J E, Campbell G D. Acute miliary blastomycosis presenting as fluminating respiratory failure.  Chest. 1979;  75 (5) 630-632
  • 48 Berger R, Kraman S. Acute miliary blastomycosis after ‘short-course’ corticosteroid treatment.  Arch Intern Med. 1981;  141 (9) 1223-1225
  • 49 Stelling C B, Woodring J H, Rehm S R, Hopper D W, Noble R C. Miliary pulmonary blastomycosis.  Radiology. 1984;  150 (1) 7-13
  • 50 Evans M E, Haynes J B, Atkinson J B, Delvaux Jr T C, Kaiser A B. Blastomyces dermatitidis and the adult respiratory distress syndrome: case reports and review of the literature.  Am Rev Respir Dis. 1982;  126 (6) 1099-1102
  • 51 Thiele J S, Buechner H A, Deshotels Jr S J. Blastomycosis and the adult respiratory distress syndrome.  J La State Med Soc. 1984;  136 (11) 38-40
  • 52 Skillrud D M, Douglas W W. Survival in adult respiratory distress syndrome caused by blastomycosis infection.  Mayo Clin Proc. 1985;  60 (4) 266-269
  • 53 Meyer K C, McManus E J, Maki D G. Overwhelming pulmonary blastomycosis associated with the adult respiratory distress syndrome.  N Engl J Med. 1993;  329 (17) 1231-1236
  • 54 Mukkamala R, Mehta J B, Myers J W, Cole C P. Pulmonary blastomycosis with acute respiratory failure as predominant clinical feature.  South Med J. 1997;  90 (8) 847-850
  • 55 Lemos L B, Baliga M, Guo M. Acute respiratory distress syndrome and blastomycosis: presentation of nine cases and review of the literature.  Ann Diagn Pathol. 2001;  5 (1) 1-9
  • 56 Lemos L B, Guo M, Baliga M. Blastomycosis: organ involvement and etiologic diagnosis. A review of 123 patients from Mississippi.  Ann Diagn Pathol. 2000;  4 (6) 391-406
  • 57 Martynowicz M A, Prakash U B. Pulmonary blastomycosis: an appraisal of diagnostic techniques.  Chest. 2002;  121 (3) 768-773
  • 58 Hage C A, Davis T E, Fuller D et al.. Diagnosis of histoplasmosis by antigen detection in BAL fluid.  Chest. 2010;  137 (3) 623-628
  • 59 Patel A J, Gattuso P, Reddy V B. Diagnosis of blastomycosis in surgical pathology and cytopathology: correlation with microbiologic culture.  Am J Surg Pathol. 2010;  34 (2) 256-261
  • 60 Durkin M, Witt J, Lemonte A, Wheat B, Connolly P. Antigen assay with the potential to aid in diagnosis of blastomycosis.  J Clin Microbiol. 2004;  42 (10) 4873-4875
  • 61 Turner S, Kaufman L. Immunodiagnosis of blastomycosis.  Semin Respir Infect. 1986;  1 (1) 22-28
  • 62 Bradsher R W, Pappas P G. Detection of specific antibodies in human blastomycosis by enzyme immunoassay.  South Med J. 1995;  88 (12) 1256-1259
  • 63 Klein B S, Vergeront J M, Kaufman L et al.. Serological tests for blastomycosis: assessments during a large point-source outbreak in Wisconsin.  J Infect Dis. 1987;  155 (2) 262-268
  • 64 Klein B S, Jones J M. Isolation, purification, and radiolabeling of a novel 120-kD surface protein on Blastomyces dermatitidis yeasts to detect antibody in infected patients.  J Clin Invest. 1990;  85 (1) 152-161
  • 65 Soufleris A J, Klein B S, Courtney B T, Proctor M E, Jones J M. Utility of anti-WI-1 serological testing in the diagnosis of blastomycosis in Wisconsin residents.  Clin Infect Dis. 1994;  19 (1) 87-92
  • 66 Sarosi G A, Davies S F, Phillips J R. Self-limited blastomycosis: a report of 39 cases.  Semin Respir Infect. 1986;  1 (1) 40-44
  • 67 Recht L D, Philips J R, Eckman M R, Sarosi G A. Self-limited blastomycosis: a report of thirteen cases.  Am Rev Respir Dis. 1979;  120 (5) 1109-1112
  • 68 Saccente M, Woods G L. Clinical and laboratory update on blastomycosis.  Clin Microbiol Rev. 2010;  23 (2) 367-381
  • 69 Chapman S W, Dismukes W E, Proia L A Infectious Diseases Society of America et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America.  Clin Infect Dis. 2008;  46 (12) 1801-1812
  • 70 Harrell E R, Curtis A C. The treatment of North American blastomycosis with amphotericin B.  AMA Arch Derm. 1957;  76 (5) 561-568 discussion 568-569
  • 71 Busey J F. Blastomycosis: a review of 198 collected cases in VA hospitals.  Am Rev Respir Dis. 1964;  89 659-672
  • 72 Lockwood W R, Allison Jr F, Batson B E, Busey J F. The treatment of North American blastomycosis. Ten years’ experience.  Am Rev Respir Dis. 1969;  100 (3) 314-320
  • 73 Parker J D, Doto I L, Tosh F E. A decade of experience with blastomycosis and its treatment with amphotericin B. A National Communicable Disease Center Cooperative Mycoses Study.  Am Rev Respir Dis. 1969;  99 (6) 895-902
  • 74 Seabury J H, Dascomb H E. Results of the treatment of systemic mycoses.  JAMA. 1964;  188 509-513
  • 75 Abernathy R S. Amphotericin therapy of North American blastomycosis.  Antimicrob Agents Chemother (Bethesda). 1966;  6 208-211
  • 76 Busey J F. Blastomycosis, III: A comparative study of 2-hydroxystilbamidine and amphotericin B therapy.  Am Rev Respir Dis. 1972;  105 (5) 812-818
  • 77 Dismukes W E, Stamm A M, Graybill J R et al.. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study.  Ann Intern Med. 1983;  98 (1) 13-20
  • 78 National Institute of Allergy and Infectious Diseases Mycoses Study Group . Treatment of blastomycosis and histoplasmosis with ketoconazole: results of a prospective randomized clinical trial.  Ann Intern Med. 1985;  103 (6 Pt 1) 861-872
  • 79 Pitrak D L, Andersen B R. Cerebral blastomycoma after ketoconazole therapy for respiratory tract blastomycosis.  Am J Med. 1989;  86 (6 Pt 1) 713-714
  • 80 Dismukes W E, Bradsher Jr R W, Cloud G C NIAID Mycoses Study Group et al. Itraconazole therapy for blastomycosis and histoplasmosis.  Am J Med. 1992;  93 (5) 489-497
  • 81 Bradsher R W. Blastomycosis.  Clin Infect Dis. 1992;  14 (Suppl 1) S82-S90
  • 82 Dodds Ashley E, Lewis R, Lewis J et al.. Pharmacology of systemic antifungal agents.  Clin Infect Dis. 2006;  43 (Suppl 1) S28-S39
  • 83 Pappas P G, Bradsher R W, Chapman S W The National Institute of Allergy and Infectious Diseases Mycoses Study Group et al. Treatment of blastomycosis with fluconazole: a pilot study.  Clin Infect Dis. 1995;  20 (2) 267-271
  • 84 Pappas P G, Bradsher R W, Kauffman C A The National Institute of Allergy and Infectious Diseases Mycoses Study Group et al. Treatment of blastomycosis with higher doses of fluconazole.  Clin Infect Dis. 1997;  25 (2) 200-205
  • 85 Li R K, Ciblak M A, Nordoff N, Pasarell L, Warnock D W, McGinnis M R. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum.  Antimicrob Agents Chemother. 2000;  44 (6) 1734-1736
  • 86 Sugar A M, Liu X P. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis.  Antimicrob Agents Chemother. 2001;  45 (2) 601-604
  • 87 Freifeld A G, Bariola J R, Andes D. The role of second-generation antifungal triazoles for treatment of the endemic mycoses.  Curr Infect Dis Rep. 2010;  12 (6) 471-478
  • 88 Bakleh M, Aksamit A J, Tleyjeh I M, Marshall W F. Successful treatment of cerebral blastomycosis with voriconazole.  Clin Infect Dis. 2005;  40 (9) e69-e71
  • 89 Borgia S M, Fuller J D, Sarabia A, El-Helou P. Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimen.  Med Mycol. 2006;  44 (7) 659-664
  • 90 Panicker J, Walsh T, Kamani N. Recurrent central nervous system blastomycosis in an immunocompetent child treated successfully with sequential liposomal amphotericin B and voriconazole.  Pediatr Infect Dis J. 2006;  25 (4) 377-379
  • 91 Freifeld A, Proia L, Andes D et al.. Voriconazole use for endemic fungal infections.  Antimicrob Agents Chemother. 2009;  53 (4) 1648-1651
  • 92 Bariola J R, Perry P, Pappas P G et al.. Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era.  Clin Infect Dis. 2010;  50 (6) 797-804
  • 93 Sabatelli F, Patel R, Mann P A et al.. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.  Antimicrob Agents Chemother. 2006;  50 (6) 2009-2015
  • 94 Sugar A M, Liu X P. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis.  Antimicrob Agents Chemother. 1996;  40 (5) 1314-1316
  • 95 Zhanel G G, Karlowsky J A, Harding G A et al.. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.  Antimicrob Agents Chemother. 1997;  41 (4) 863-865
  • 96 Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.  J Clin Microbiol. 1998;  36 (10) 2950-2956
  • 97 Vasquez J E, Mehta J B, Agrawal R, Sarubbi F A. Blastomycosis in northeast Tennessee.  Chest. 1998;  114 (2) 436-443
  • 98 Lahm T, Neese S, Thornburg A T, Ober M D, Sarosi G A, Hage C A. Corticosteroids for blastomycosis-induced ARDS: a report of two patients and review of the literature.  Chest. 2008;  133 (6) 1478-1480
  • 99 Plamondon M, Lamontagne F, Allard C, Pépin J. Corticosteroids as adjunctive therapy in severe blastomycosis-induced acute respiratory distress syndrome in an immunosuppressed patient.  Clin Infect Dis. 2010;  51 (1) e1-e3
  • 100 Wüthrich M, Chang W L, Klein B S. Immunogenicity and protective efficacy of the WI-1 adhesin of Blastomyces dermatitidis.  Infect Immun. 1998;  66 (11) 5443-5449
  • 101 Klein B S. Molecular basis of pathogenicity in Blastomyces dermatitidis: the importance of adhesion.  Curr Opin Microbiol. 2000;  3 (4) 339-343
  • 102 Wüthrich M, Krajaejun T, Shearn-Bochsler V et al.. Safety, tolerability, and immunogenicity of a recombinant, genetically engineered, live-attenuated vaccine against canine blastomycosis.  Clin Vaccine Immunol. 2011;  18 (5) 783-789

J. Ryan BariolaM.D. 

Division of Infectious Diseases, University of Arkansas for Medical Sciences

4301 W. Markham St., Mail Slot #639, Little Rock, AR 72205

Email: bariolajeremyr@uams.edu

    >